FDA warning letters to compounding pharmacies — June 2026 roundup

Let me be real with you: those three findings are not minor. Let me translate: #1 — Water quality failure: Water is the most fundamental component in sterile compounding. If they can't verify their water meets USP standards (Water for Injection grade for parenteral products), then EVERY product they make is potentially compromised. Water touches everything. This isn't "we forgot to document one test" — this suggests a systemic gap in their water system validation. #2 — Production procedure failures: This means their SOPs (Standard Operating Procedures) for actually making the products are inadequate. Either they don't have written procedures, or the procedures are incomplete, or staff aren't following them. This is foundational cGMP stuff. #3 — Uninvestigated discrepancies: This one scares me the most. "Discrepancies" in pharma means something unexpected happened — an out-of-spec test result, an environmental monitoring excursion, a batch that didn't meet specifications. The FDA found that when these things happened, the pharmacy didn't adequately investigate WHY. They either ignored the problems or wrote them off without root-cause analysis. This tells me the quality CULTURE has issues, not just specific procedures. The pharmacy's response to unexpected results is to not investigate them. That's how contaminated products reach patients.

Yikes. But I haven't had any problems. Does that count for anything?

It counts for something — it means you personally haven't been affected YET. But consider: 1. You can't see contamination. A vial can look perfect, clear, no particles — and still contain endotoxins, subvisible particulates, or degradation products. You'd need analytical testing to detect these. 2. You can't assess potency by effect alone. If your semaglutide is 85% potency instead of the labeled 100%, you'd likely still see some weight loss effect. You just wouldn't know you're getting 15% less drug than you're paying for. 3. Warning Letters represent a SNAPSHOT. The FDA found these issues during a specific inspection. They may have existed for the entire 8 months you've been a customer. You've been using products from a facility with unverified water quality and inadequate process controls — you just didn't know it. 4. The risk is probabilistic, not deterministic. Not every product from a non-compliant facility is bad. But the PROBABILITY of a bad product is higher than from a compliant facility. You've been playing a game with better odds than you realized were against you. I'm not saying your products were definitely compromised. I'm saying the FDA found conditions that increase the risk of product quality failures, and you have no way to independently verify that your specific vials were fine.

I'll add some context on what typically happens after a Warning Letter: Timeline after a Warning Letter: 1. 15 business days: Pharmacy must respond in writing with corrective action plan 2. 3-6 months: Pharmacy implements corrective actions 3. 6-18 months: FDA typically conducts a follow-up inspection 4. If issues resolved: No further action 5. If issues NOT resolved: Escalation — possible consent decree, injunction, or forced closure What you should consider: - A pharmacy that takes a Warning Letter seriously, hires quality consultants, invests in corrections, and demonstrates genuine improvement can come out stronger. Some of the best pharmacies in the industry today have Warning Letters in their history. - A pharmacy that fights the FDA, minimizes the findings, or makes cosmetic changes without addressing root causes is likely to have ongoing problems. How to gauge which category your pharmacy falls into: 1. Call them and ask directly about the Warning Letter 2. Ask what corrective actions they've taken 3. Ask if they've hired any outside quality consultants 4. Ask if they've voluntarily paused any operations during remediation 5. Gauge their tone — are they transparent and accountable, or defensive and dismissive? The response tells you everything about the culture.